News & Updates
Filter by Specialty:
High red meat consumption increases risks of CVD and diabetes
Higher consumption of both unprocessed and processed red meat is associated with higher risks of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), according to a meta-analysis involving >4.4 million people by researchers from the University of Hong Kong (HKU).
High red meat consumption increases risks of CVD and diabetes
27 Oct 2023
Oral health checks integral to diabetes management
A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.
Oral health checks integral to diabetes management
24 Oct 2023
Roflumilast serves up weight-loss benefit for patients with psoriasis
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.
Roflumilast serves up weight-loss benefit for patients with psoriasis
20 Oct 2023
Newly diagnosed T2D linked to earlier CVD events
A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.
Newly diagnosed T2D linked to earlier CVD events
20 Oct 2023
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
19 Oct 2023
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.